2μg (R: reducing condition, N: non-reducing condition).
Product Details
Product Details
Product Specification
Species | Human |
Synonyms | Inositol 1,4,5-trisphosphate receptor-interacting protein-like 1; ITPRIPL1; KIAA1754L; CD3L1 |
Accession | Q6GPH6 |
Concentration | >95% by SDS-PAGE & SEC-HPLC |
Amino Acid Sequence | His25-Gly103 with His Tag at the C-Terminus |
Expression System | HEK293 |
Molecular Weight | 10-15kDa (Reducing) |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | His Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, PH7.4, 5% trehalose |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
Reference |
1. Shouyan Deng, et al. The ITPRIPL1- CD3ε axis: a novel immune checkpoint controlling T cells activation. bioRxiv, 2022. 2. Zhong, X. and Zhong, G. Prognostic biomarker identification and tumor classification in breast cancer patients by methylation and transcriptome analysis. FEBS Open Bio, 2021. |
Background
Inositol 1,4,5-trisphosphate Receptor Interacting Protein-Like 1 (ITPRIPL1) is a transmembrane protein that is widely expressed in the testis and is associated with immune evasion mechanisms. ITPRIPL1 is specifically expressed in immune-privileged tissues, 'hot' tumors lacking PD-L1 expression, and tumors that do not respond to PD-1 blockade therapy. Experimental evidence has demonstrated that ITPRIPL1 can impair T cell function both in vitro and in vivo through interactions with CD3e, with a negative correlation observed between ITPRIPL1 expression levels in antigen-presenting cells and T cell cytotoxicity.
In the context of breast cancer, ITPRIPL1 has been identified as a hypermethylated, low-expression gene. Furthermore, using bioinformatics methods, ITPRIPL1 has been established as an independent biomarker for the prognosis of lung adenocarcinoma. Therefore, targeting the ITPRIPL1-CD3e axis, particularly in patients with PD-1/PD-L1 negative tumors, represents a promising therapeutic strategy to mitigate immune evasion.
ITPRIPL1 is also a significant biomarker for non-small cell lung cancer (NSCLC). The detection of ITPRIPL1 in tumors can aid in improved diagnosis, reveal the infiltration of CD8 positive T cells, monitor disease progression, and predict prognosis.
Picture
Picture
SDS-PAGE
SEC-HPLC
The purity of ITPRIPL1 His Tag Protein, Human is greater than 95% as determined by SEC-HPLC.
ELISA

Immobilized ITPRIPL1 His Tag Protein, Human (Cat. No. UA011092) at 2.0μg/mL (100μL/well) can bind CD3L1 (ITPRIPL1) Recombinant Rabbit mAb (S-1716-50) (Cat. No. S0B1227) with EC50 of 0.87-1.24 ng/ mL.
